An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-Deficit/Hyperactivity Disorder

Trial Profile

An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-Deficit/Hyperactivity Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2010

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Dec 2009 Actual patient number (45) added as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top